Lumicitabine
Sponsors
Janssen Research & Development, LLC
Conditions
HealthyMetapneumovirusRespiratory Syncytial Virus InfectionsRespiratory Syncytial Viruses
Phase 1
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
CompletedNCT03441529
Start: 2018-02-09End: 2018-05-03Updated: 2018-06-07
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
TerminatedNCT03468777
Start: 2018-03-06End: 2018-07-09Updated: 2018-07-23
Phase 2
Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus
TerminatedNCT02935673
Start: 2016-10-25End: 2018-07-17Updated: 2019-12-24
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
TerminatedNCT03333317
Start: 2017-11-24End: 2018-03-23Updated: 2019-12-23
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
CompletedNCT03332459
Start: 2018-01-05End: 2020-04-13Updated: 2021-04-13
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
WithdrawnNCT03502694
Start: 2018-11-05End: 2020-10-28Updated: 2018-11-15